Evidence map›Paper›PMID 33658928›Full record

ArticleFrontiers in pharmacology2020

Treatment of Spleen-Deficiency Syndrome With Atractyloside A From Bran-Processed

Jiyuan Tu, Ying Xie, Kang Xu, Linghang Qu, Xiong Lin, Chang Ke, Desen Yang, Guosheng Cao, Zhongshi Zhou, Yanju Liu

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Phytochemistry and Pharmacology of Sesquiterpenoids fromMolecules (Basel, Switzerland) · 2024
    Review
  7. Article
  8. Article
  9. Review
  10. Effectiveness of Fuling () and its extracts against spleen deficiency in rats tonifying spleen.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2023
    Article
  11. Review
  12. Article
  13. Article
  14. Frontiers in pharmacology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Jiyuan TuSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, China.
Ying XieSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, China.
Kang XuSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, China.
Linghang QuSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, China.
Xiong LinSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, China.
Chang KeSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, China.
Desen YangSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, China.
Guosheng CaoSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, China.
Zhongshi ZhouSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, China.
Yanju LiuSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, China.
Hubei University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Atractyloside Aintestinal mucosal barriernetwork pharmacologyp38 MAPKspleen-deficiency syndrome

Identifiers

PMID33658928
PMCPMC7919195
OpenAlexW3109472797

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.